Acute Lymphoblastic Leukemia, Pediatric
34
13
16
11
Key Insights
Highlights
Success Rate
85% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 62/100
5.9%
2 terminated out of 34 trials
84.6%
-1.9% vs benchmark
9%
3 trials in Phase 3/4
9%
1 of 11 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 11 completed trials
Clinical Trials (34)
Behavioral Parenting Skills as a Novel Target for Improving Pediatric Medication Adherence: Study 3
Palbociclib in Combo w/Chemotherapy in Peds Relapsed/Refractory Acute Lymphoblastic Leukemia
Massage Impact on Sleep in Pediatric Oncology
Brain MRF in Children, Adolescents and Young Adults With Acute Leukemia
Vaccine Immune Recovery After Leukemia
Treatment of Newly Diagnosed Acute Lymphoblastic Leukemia in Children and Adolescents
CAR-20/19-T Cells in Patients With Relapsed/Refractory B Cell ALL
A Phase I Dose Finding Study of MB-CART2219.1
Biology and Benefits of Music Play and Stories for Kids/Parents During ALL Treatment
Treatment of Pediatric Very High-risk Acute Lymphoblastic Leukemia in Korea
Phase II Study of Anti-CD19 CAR-T Cells Treating Leukemia Children
Treatment Protocol for Children and Adolescents With Acute Lymphoblastic Leukemia - AIEOP-BFM ALL 2017
CD22-CAR T Cells in Children and Young Adults With B Cell Malignancies
CD-19 CAR-T Cell for Pediatric ALL or Lymphoma
Low GI Diet in Children and Adolescents With ALL
A Prospective, Open-label, Randomized Controlled, Multicenter Clinical Study of Haplo-HSCT Using a TBI or TMLI Conditioning Regimen for Pediatric ALL
A Prospective, Open-label, Randomized Controlled, Multicenter Clinical Study of MSD-HSCT Using a TBI or TMLI Conditioning Regimen for Pediatric ALL
Virtual Reality During Lumbar Punctures in Acute Lymphoblastic Leukemia
Healthy Bones, Healthy Life: Habitual Physical Activity on Bone & Metabolic Health in Pediatric Cancer Survivors
MRD Detection by NGS in Pediatric T-ALL